Ophidion
Pasadena
About Ophidion
Ophidion is a biotechnology company that delivers a central nervous system therapeutics to targeted sites in the brain. The company uses a Trojan horse strategy to exploit an endogenous receptor-mediated transport system to deliver small molecule drugs and biologics into the brain. They are currently focused on developing a pipeline to deliver gene-silencing therapies to treat neurodegenerative diseases, including diseases of Cognitive Impairment (e.g. Alzheimer’s disease, Parkinson’s disease) as well as Huntington’s disease. Ophidion platform technology is amenable to delivering multiple classes of drugs, including small molecules and macromolecules (gene therapeutics, siRNA’s, antibodies, peptides, and other macromolecules). It also has an advanced program that is positioned to start pivotal clinical trials to treat anxiety-related disorders, together with a patented companion biomarker diagnostic to select the appropriate patient population.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $1.9M
- Last round: Undisclosed (Sep 2024)
- Website: ophidion.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Therapeutics
Canonical: https://fsome.com/organization/ophidion-93995 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.